Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Expert Review of Molecular Diagnostics Année : 2015

Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay

Résumé

Circulating tumor cells (CTCs) in the blood of cancer patients have received increasing attention as new diagnostic tool enabling 'liquid biopsies'. In contrast to the wealth of descriptive studies demonstrating the clinical relevance of CTCs as biomarkers, the extremely low concentration of CTCs in the peripheral blood of most cancer patients challenges further functional studies. This article discusses the current possibilities to enrich and, in particular, detect viable CTCs with emphasis on the EPithelial ImmunoSPOT technology. This functional assay detects viable CTCs at the single-cell level and has been used on hundreds of patients with different tumor types including epithelial tumors (breast, prostate and colon cancer) and melanomas. Moreover, the article summarizes recent advances in the in vitro and in vivo expansion of CTCs from cancer patients. These functional analyses will contribute to identifying the biological properties of metastatic cells and reveal new therapeutic targets against disseminating cancer cells.
Fichier non déposé

Dates et versions

hal-01945648 , version 1 (05-12-2018)

Identifiants

Citer

Catherine Alix-Panabières, Klaus Pantel. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Review of Molecular Diagnostics, 2015, 15 (11), pp.1411-1417. ⟨10.1586/14737159.2015.1091729⟩. ⟨hal-01945648⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More